HLA-matched sibling transplantations and unrelated donor transplantations: results of multivariate analysis for acute GVHD, chronic GVHD, nonrelapse mortality, relapse, disease-free survival, and overall survival
| Outcome . | HR (95% CI) . | P . |
|---|---|---|
| HLA-matched sibling transplantations | ||
| Grade 2-4 acute GVHD | ||
| ATG regimen vs T cell–replete regimen | 0.77 (0.58-1.02) | .06 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.34 (0.16-0.69) | .003 |
| Grade 3-4 acute GVHD | ||
| ATG regimen vs T cell–replete regimen | 0.64 (0.44-0.94) | .02 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.49 (0.21-1.14) | .10 |
| Chronic GVHD | ||
| ATG regimen vs T cell–replete regimen | 0.69 (0.54-0.90) | .006 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.34 (0.16-0.72) | .005 |
| Non-relapse mortality | ||
| ATG regimen vs T cell–replete regimen | 1.35 (0.97-1.88) | .08 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.82 (0.39-1.73) | .60 |
| Relapse | ||
| ATG regimen vs T cell–replete regimen | 1.35 (1.04-1.74) | .02 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.83 (1.14-2.91) | .01 |
| Treatment failure (inverse of disease-free survival) | ||
| ATG regimen vs T cell–replete regimen | 1.31 (1.07-1.60) | .008 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.47 (1.00-2.16) | .05 |
| Overall mortality | ||
| ATG regimen vs T cell–replete regimen | 1.28 (1.03-1.59) | .03 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.31 (0.85-2.01) | .23 |
| Unrelated donor transplantations | ||
| Grade 2-4 acute GVHD | ||
| ATG regimen vs T cell–replete regimen | 0.97 (0.78-1.20) | .75 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.36 (0.25-0.52) | < .001 |
| Grade 3-4 acute GVHD | ||
| ATG regimen vs T cell–replete regimen | 1.02 (0.76-1.37) | .89 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.46 (0.28-0.77) | .003 |
| Chronic GVHD | ||
| ATG regimen vs T cell–replete regimen | 0.68 (0.55-0.84) | < .001 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.34 (0.24-0.46) | < .001 |
| Non-relapse mortality | ||
| ATG regimen vs T cell–replete regimen | 1.56 (1.13-2.14) | .007 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.12 (0.72-1.74) | .61 |
| Relapse | ||
| ATG regimen vs T cell–replete regimen | 1.45 (1.15-1.83) | .002 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.42 (1.07-1.90) | .02 |
| Treatment failure (inverse of disease-free survival) | ||
| ATG regimen vs T cell–replete regimen | 1.50 (1.25-1.78) | < .001 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.29 (1.03-1.61) | .03 |
| Overall mortality | ||
| ATG regimen vs T cell–replete regimen | 1.25 (1.03-1.52) | .02 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.02 (0.78-1.34) | .89 |
| Outcome . | HR (95% CI) . | P . |
|---|---|---|
| HLA-matched sibling transplantations | ||
| Grade 2-4 acute GVHD | ||
| ATG regimen vs T cell–replete regimen | 0.77 (0.58-1.02) | .06 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.34 (0.16-0.69) | .003 |
| Grade 3-4 acute GVHD | ||
| ATG regimen vs T cell–replete regimen | 0.64 (0.44-0.94) | .02 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.49 (0.21-1.14) | .10 |
| Chronic GVHD | ||
| ATG regimen vs T cell–replete regimen | 0.69 (0.54-0.90) | .006 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.34 (0.16-0.72) | .005 |
| Non-relapse mortality | ||
| ATG regimen vs T cell–replete regimen | 1.35 (0.97-1.88) | .08 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.82 (0.39-1.73) | .60 |
| Relapse | ||
| ATG regimen vs T cell–replete regimen | 1.35 (1.04-1.74) | .02 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.83 (1.14-2.91) | .01 |
| Treatment failure (inverse of disease-free survival) | ||
| ATG regimen vs T cell–replete regimen | 1.31 (1.07-1.60) | .008 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.47 (1.00-2.16) | .05 |
| Overall mortality | ||
| ATG regimen vs T cell–replete regimen | 1.28 (1.03-1.59) | .03 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.31 (0.85-2.01) | .23 |
| Unrelated donor transplantations | ||
| Grade 2-4 acute GVHD | ||
| ATG regimen vs T cell–replete regimen | 0.97 (0.78-1.20) | .75 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.36 (0.25-0.52) | < .001 |
| Grade 3-4 acute GVHD | ||
| ATG regimen vs T cell–replete regimen | 1.02 (0.76-1.37) | .89 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.46 (0.28-0.77) | .003 |
| Chronic GVHD | ||
| ATG regimen vs T cell–replete regimen | 0.68 (0.55-0.84) | < .001 |
| Alemtuzumab regimen vs T cell–replete regimen | 0.34 (0.24-0.46) | < .001 |
| Non-relapse mortality | ||
| ATG regimen vs T cell–replete regimen | 1.56 (1.13-2.14) | .007 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.12 (0.72-1.74) | .61 |
| Relapse | ||
| ATG regimen vs T cell–replete regimen | 1.45 (1.15-1.83) | .002 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.42 (1.07-1.90) | .02 |
| Treatment failure (inverse of disease-free survival) | ||
| ATG regimen vs T cell–replete regimen | 1.50 (1.25-1.78) | < .001 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.29 (1.03-1.61) | .03 |
| Overall mortality | ||
| ATG regimen vs T cell–replete regimen | 1.25 (1.03-1.52) | .02 |
| Alemtuzumab regimen vs T cell–replete regimen | 1.02 (0.78-1.34) | .89 |